Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$41.01 USD

41.01
1,000,317

-1.41 (-3.32%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Phillips' (PHG) Partner Base Expansion Drives Prospects

by Zacks Equity Research

Phillips (PHG) signed a long-term agreement with IJsselland Hospital to facilitate digitization and innovation in healthcare.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients

by Zacks Equity Research

Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.

HCA Healthcare (HCA) Up 53.3% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare's (HCA) strategic measures and strong patient volumes will likely lead to better revenues, thus perking up its share price.

Tenet Healthcare (THC) Soars 95.8% YTD: More Room to Run?

by Zacks Equity Research

Banking on a solid guidance, enhanced portfolio and strategic measures, Tenet Healthcare (THC) holds enough potential to reap benefits for investors.

    BD's (BDX) Latest Buyout to Enhance its Digital Capabilities

    by Zacks Equity Research

    BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.

    Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

    Here's Why You Should Retain Masimo (MASI) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

    Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.

    Acadia Healthcare (ACHC) Buys Real Estate to Expand in Chicago

    by Zacks Equity Research

    Acadia Healthcare (ACHC) purchases real estate in Illinois to serve the local communities with better healthcare facilities.

      Ensign Group (ENSG) Hikes Dividend to Share More Profits

      by Zacks Equity Research

      Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.

      Here's Why You Should Retain DexCom (DXCM) Stock For Now

      by Zacks Equity Research

      Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

      Here's Why You Should Retain Catalent (CTLT) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.

      Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.

      FDA Approves Intuitive Surgical's (ISRG) Latest SureForm Stapler

      by Zacks Equity Research

      Intuitive Surgical's (ISRG) newest stapler is expected to result in better surgical outcomes.

      Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence

      by Zacks Equity Research

      Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.

      Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

      by Zacks Equity Research

      Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

      Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

      by Zacks Equity Research

      Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

      Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

      by Zacks Equity Research

      Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

      Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about Veeva Systems (VEEV) owing to its strong product portfolio.

      Study Favors Masimo's (MASI) SedLine for Better Patient Outcome

      by Zacks Equity Research

      Masimo's (MASI) SedLine is expected to aid in the early identification of patients who are at risk of developing POD.

      CVS Health (CVS) Scales a 52-Week High: What's Driving It?

      by Zacks Equity Research

      Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).

      Hologic (HOLX) Reports New Findings on Breast Cancer Index

      by Zacks Equity Research

      Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.